Weed Inc
OTC:BUDZ
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Weed Inc
Non-Reccuring Items
Weed Inc
Non-Reccuring Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Non-Reccuring Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Weed Inc
OTC:BUDZ
|
Non-Reccuring Items
-$600
|
CAGR 3-Years
90%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Non-Reccuring Items
-$2.4B
|
CAGR 3-Years
38%
|
CAGR 5-Years
13%
|
CAGR 10-Years
-10%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Non-Reccuring Items
-$6.9B
|
CAGR 3-Years
-59%
|
CAGR 5-Years
12%
|
CAGR 10-Years
-24%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Non-Reccuring Items
-$10.2B
|
CAGR 3-Years
-38%
|
CAGR 5-Years
-31%
|
CAGR 10-Years
-12%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Non-Reccuring Items
-$5.6B
|
CAGR 3-Years
-33%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-6%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Non-Reccuring Items
-$3.4B
|
CAGR 3-Years
-43%
|
CAGR 5-Years
-34%
|
CAGR 10-Years
-12%
|
|
Weed Inc
Glance View
WEED, Inc. operates as a holding company, which engages on the development and application of cannabis-derived compounds for the treatment of human disease. The company is headquartered in Tucson, Arizona and currently employs 2 full-time employees. The company went IPO on 2010-11-10. The firm and its subsidiaries are focused on various business opportunities in the cannabis and hemp field, including, but not limited to both indoor and outdoor grows, cultivations and harvest for research, product development, processing and manufacturing of both pharma and non-pharma products, services, therapeutics, and treatments on a global basis for both the medical cannabis and hemp global market space. Its first business opportunity is through its wholly owned subsidiary, Sangre AT, LLC (Sangre), where it is focused on the development and application of cannabis-derived compounds for the treatment of human disease and animal ailments.
See Also
What is Weed Inc's Non-Reccuring Items?
Non-Reccuring Items
-600
USD
Based on the financial report for Dec 31, 2025, Weed Inc's Non-Reccuring Items amounts to -600 USD.
What is Weed Inc's Non-Reccuring Items growth rate?
Non-Reccuring Items CAGR 3Y
90%
The average annual Non-Reccuring Items growth rates for Weed Inc have been 90% over the past three years .
